The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1084/jem.20092160
The Journal of Experimental Medicine, Vol. 206, No. 11, 2309-2312
The Rockefeller University Press, 0022-1007 $30.00
© Vucic et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1327K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Vucic, D.
Right arrow Articles by Dixit, V. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vucic, D.
Right arrow Articles by Dixit, V. M.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Commentary

 Masking MALT1: the paracaspase's potential for cancer therapy

Domagoj Vucic and Vishva M. Dixit

D.V. and V.M.D. are at Department of Protein Engineering and Department of Physiological Chemistry, Genentech, Inc., South San Francisco, CA 94080

CORRESPONDENCE D.V.: vucic.domagoj{at}gene.com


ABSTRACT
A key feature of aggressive B cell lymphomas is constitutive NF-{kappa}B activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-{kappa}B inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.

© 2009 Vucic and Dixit
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells
Uta Ferch, Bernhard Kloo, Andreas Gewies, Vera Pfänder, Michael Düwel, Christian Peschel, Daniel Krappmann, and Jürgen Ruland
J. Exp. Med. 2009 206: 2313-2320. [Abstract] [Full Text] [PDF]





  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS